论文部分内容阅读
近年来阴性杆菌感染特别是绿脓杆菌与大肠杆菌引起的感染发病率有所增加,治疗比较困难,失败率较高。抗阴性杆菌抗菌素虽已有不少品种,但能有效控制绿脓杆菌与耐药大肠杆菌感染的抗菌素为数不多,而且存在不少问题,很难满足临床需要。多粘菌素类抗菌素体外对绿脓杆菌与大肠杆菌均有较好杀菌作用,但因对肾脏具有一定毒性,治疗剂量受到严格限制,对重症感染的疗效并不满意。庆大霉素是目前
In recent years, negative bacilli infections, especially Pseudomonas aeruginosa and Escherichia coli caused an increase in the incidence of infection, the treatment is more difficult, a higher failure rate. Antibacterial antibacterial bacilli Although there are many varieties, but can effectively control the Pseudomonas aeruginosa and drug-resistant Escherichia coli antibiotic is one of the few, but there are many problems, it is difficult to meet the clinical needs. Polymyxins antibiotics in vitro against Pseudomonas aeruginosa and Escherichia coli have a good bactericidal effect, but due to the kidney has a certain toxicity, the treatment dose is severely limited, the efficacy of severe infections are not satisfied. Gentamicin is currently